News

To celebrate the Canadian Angelman Syndrome Society’s (CASS) 25th anniversary, the society hosted its 2018 annual conference April 20-21, in Toronto, Ontario. The conference, held at the Omni King Edward Hotel in downtown Toronto, provided the Angelman syndrome (AS) community a weekend of team-building, education and empowerment. The…

Taurine was able to recover motor capacity, learning and memory skills in a mouse model of Angelman syndrome, indicating the compound may be a potential therapy to treat motor and cognitive deficits in Angelman patients. The study “Taurine Administration Recovers Motor and…

In vitro fertilization (IVF) appears to increase the risk of Angelman syndrome as a result of a genetic mechanism known as an imprinting error, according to a study of IVF pregnancies. Several studies have indicated that IVF is accompanied by an increased risk of certain conditions with imprinting disorders, such as…

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

Early and careful detection of the spectrum of neurodevelopmental disabilities in children with Angelman syndrome is essential to planning personalized rehabilitation programs and improving outcomes, research suggests. These findings emphasize the need for early diagnosis, particularly of neurovisual disorders, which can seriously contribute to cognitive impairment…

Oral diazepam is an effective treatment for Angelman syndrome patients who have prolonged seizure activity without convulsions, a study shows. It is also safe, researchers said. The study, “Diazepam for outpatient treatment of nonconvulsive status epilepticus in pediatric patients with Angelman syndrome,” appeared in the journal Epilepsy & Behaviors. Diazepam,…

The U.S.’s fifth Angelman syndrome clinic has opened at Vanderbilt University Medical Center in Nashville. The Angelman Syndrome Clinic at Vanderbilt was established with support from the Angelman Syndrome Foundation. It will offer a variety of resources, preventing patients from having to go to several facilities across the nation…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GTX-101, GeneTx Biotherapeutics’s investigational compound for the treatment of Angelman syndrome. GTX-101, which is GeneTx’s first drug candidate, is an antisense therapy that can silence gene expression by binding to the RNA molecule that converts the gene into a…

Two equally rare diseases — Angelman and Prader-Willi syndrome — originate from the same genetic deletion, but lead to radically different outcomes. These two disorders, along with dup15q syndrome, form the core of research by Stormy Chamberlain, PhD, an associate professor of genetics and genome sciences…

A possible reason for the reduced ocular pigmentation — the pale eyes — found in people with Angelman syndrome and Prader-Willi syndrome was described by scientists at Vanderbilt University Medical Center. The research team found that mice lacking the GABRB3 gene have nearly complete loss of retinal pigmentation. Since this gene is…